Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System

This study is not yet open for participant recruitment.
Verified February 2013 by South Orange County Endocrinology
Sponsor:
Collaborator:
Mannkind Corporation
Information provided by (Responsible Party):
South Orange County Endocrinology
ClinicalTrials.gov Identifier:
NCT01459133
First received: October 21, 2011
Last updated: February 6, 2013
Last verified: February 2013

October 21, 2011
February 6, 2013
May 2013
October 2014   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01459133 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System
Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere

The purpose of this program is to allow patients with diabetes and with specific medical needs which require them to use this investigational inhaled insulin product in order to adequately manage their diabetes. Treatment use of this investigational product is only anticipated when exceptional need is identified by a treating physician on a per patient case by case review.

This program is for patients who have been diagnosed with diabetes mellitus and has established a need for treatment with this investigational product documented by a health care professional. The treating doctor, or a member of his/her staff, will discuss the specific requirements for participation with the subject.

INVESTIGATIONAL PRODUCT DESCRIPTION:

Technosphere® Insulin Inhalation System includes Technosphere® Insulin Inhalation Powder and inhaler. The Inhalation Powder comes in 10 unit and 20 unit cartridges.

Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetes
Drug: Technosphere® Insulin Inhalation System
Single Site, Single Subject use of Technosphere® Insulin Inhalation System
Experimental: Technosphere® Insulin Inhalation System
Single Site, Single Subject use of Technosphere® Insulin Inhalation System
Intervention: Drug: Technosphere® Insulin Inhalation System
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
1
October 2015
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

Documented diagnosis with diabetes mellitus and have established a need for treatment with the investigational product.

Local Ethics Committee approval has been documented, as needed. Patient has signed the Informed Consent Form for participation. Patient has successfully completed training on the Technosphere Insulin Inhalation System.

Exclusion Criteria:

Allergy to Insulin. Smoking in the previous 6-months. History of asthma or COPD or any other significant pulmonary disease, or exposure to pulmonary toxins.

Clinical significant abnormality in screening laboratory tests. Positive pregnancy test or the intention to become pregnant. Women of childbearing age without appropriate method of contraception.

Both
18 Years and older
No
Not Provided
United States
 
NCT01459133
IND110021
No
South Orange County Endocrinology
South Orange County Endocrinology
Mannkind Corporation
Not Provided
South Orange County Endocrinology
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP